跳到正文
MarketHOT
English
摘要
SEC · EDGAR 财务披露·· 13 天前AI 评分20

Genmab A/S 提交 2026 年 11 月 Form 6-K 文件

6-K - GENMAB A/S (0001434265) (Filer)

AI 导读

Genmab A/S 向美国证券交易委员会提交了 2026 年 11 月 Form 6-K 外国私人发行人报告。文件将一份日期为 2026 年 11 月 5 日的中期报告列为附件,并说明该 6-K 将纳入公司部分 Form S-8 注册声明。

正文

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF NOVEMBER 2026

COMMISSION FILE NUMBER 001-38976

Genmab A/S
(Exact name of Registrant as specified in its charter)

Carl Jacobsens Vej 30

2500 Valby

Denmark

+45 70 20 27 28
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F x Form 40-F 

This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S’s registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273, 333-284876 and 333-293505) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.


EXHIBIT INDEX

ExhibitDescription of Exhibit
99.1

Interim Report Dated November 5, 2026


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

GENMAB A/S
BY:/s/ Anthony Pagano
Name: Anthony Pagano
Title: Executive Vice President & Chief Financial Officer

DATE: November 5, 2026

来源:SEC EDGAR · 本站存档